CareDx, Veracyte Enter Exclusive Partnership for Transplant Rejection Testing

100
Human heart

Precision medicine transplant care specialist CareDx and genomic diagnostics company Veracyte announced today an exclusive agreement to commercialize CAreDx’s organ transplant-rejection tests on Veracyte’s diagnostic platform, the nCounter FLEX Analysis System.

CareDx said its HistoMap gene expression profiling test, that it announced last year is under development, will run on the Veracyte system. HistoMap is being developed using the Human Organ Transplant (HOT) panel from the Banff Foundation for Allograft Pathology. CareDx will manage the global commercialization of HistoMap

“With HistoMap added to our strong KidneyCare and HeartCare offerings, we will ensure that biopsies performed are reproducibly clinically relevant. This fits well into our approach of multimodality testing and patient stratification,” said Peter Maag, chairman and CEO of CareDx, in a press release. “We are glad to partner with Veracyte to make these solutions available for transplant patients.”

The partnership with CareDx is the first by Veracyte with a diagnostics company with the aim of expanding the number of genomic tests it offers on its nCounter instrument. Veracyte acquired the global diagnostic rights to nCounter in December from NanoString Technologies. Earlier this year, Veracyte also announced its first biopharmaceutical partnership—with Acerta Pharma, the hematology research and development arm of AstraZeneca—that was enabled by the NanoString transaction.

Bonnie Anderson, Veracyte’s chairman and CEO added: “We believe this agreement will expand the menu of advanced genomic tests we offer on the nCounter platform, helping us broaden the installed base of instruments and increase adoption of our tests in global markets. Ultimately, this collaboration helps us further achieve our vision of becoming a leading global provider of advanced genomic testing.”

This site uses Akismet to reduce spam. Learn how your comment data is processed.